<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01254591</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000689973</org_study_id>
    <secondary_id>UCL-TUMOR-ANGIOGENESIS</secondary_id>
    <secondary_id>EU-21086</secondary_id>
    <nct_id>NCT01254591</nct_id>
  </id_info>
  <brief_title>Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer</brief_title>
  <official_title>Tumor Angiogenesis in Non-Small Cell Lung (NSCLC), Colorectal, Breast, Esophageal, Head and Neck Cancer: Radiology-Pathology and Prognostic Correlation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College London (UCL) Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures, such as positron emission tomography/computed tomography
      (PET/CT) scanning before surgery, may help measure the extent of disease.

      PURPOSE: This clinical trial is studying PET/CT scanning before surgery in patients with
      non-small cell lung cancer, colorectal cancer, breast cancer, esophageal cancer, or head and
      neck cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To determine the ability of preoperative fludeoxyglucose F 18 positron emission
           tomography/computed tomography (PET/CT) scanning in assessing tumor angiogenesis in
           patients with potentially operable non-small cell lung cancer, colorectal cancer, breast
           cancer, esophageal cancer, or head and neck cancer.

        -  To determine the ability of preoperative fludeoxyglucose F 18 PET/CT scanning in
           assessing prognosis by means of measuring angiogenesis in these patients.

      OUTLINE: All patients undergo fludeoxyglucose F 18 positron emission tomography/computed
      tomography (PET/CT) scanning for staging, tumor perfusion measurement/angiogenesis, and
      glucose metabolism. If staging confirms operable disease, then the patient proceeds to
      surgery as planned. Resected tumor tissue samples are examined for tumor angiogenesis in the
      various cancer types.

      Some patients undergo a half-dose of rubidium Rb-82 or 18F-fluoromisonidazole or [18F]-ML-10
      PET scan or fluorescence angiography. Patients with colorectal cancer undergo a CT scan for
      perfusion of the tumor after the staging PET/CT. Patients with breast cancer undergo infrared
      thermometry as well as a MRI scan for staging and to predict angiogenesis.

      After completion of study therapy, patients are followed up at 1 month and then every 6
      months for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2006</start_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Diagnostic</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical, radiological, and pathological correlation</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Prognosis (6-month, 1-year, 3-year, and 5-year mortality including local/distance recurrence rates)</measure>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>18F-fluoromisonidazole</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>fluorescence angiography</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>infrared thermography</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>magnetic resonance imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>[18F]-ML-10</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fludeoxyglucose F 18</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>rubidium Rb-82</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of non-small cell lung cancer, colorectal cancer, breast cancer, esophageal
             cancer, or head and neck cancer

               -  Potentially operable disease

          -  Hormone receptor status not specified

        PATIENT CHARACTERISTICS:

          -  Not specified

          -  Menopausal status not specified

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Ell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College London Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-207-631-1066</phone>
      <email>peter.ell@uclh.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2010</study_first_submitted>
  <study_first_submitted_qc>December 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2010</study_first_posted>
  <last_update_submitted>August 23, 2013</last_update_submitted>
  <last_update_submitted_qc>August 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <keyword>stage IA non-small cell lung cancer</keyword>
  <keyword>stage IB non-small cell lung cancer</keyword>
  <keyword>stage IIA non-small cell lung cancer</keyword>
  <keyword>stage IIB non-small cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage I colon cancer</keyword>
  <keyword>stage IIA colon cancer</keyword>
  <keyword>stage IIB colon cancer</keyword>
  <keyword>stage IIC colon cancer</keyword>
  <keyword>stage IIIA colon cancer</keyword>
  <keyword>stage I rectal cancer</keyword>
  <keyword>stage IIA rectal cancer</keyword>
  <keyword>stage IIB rectal cancer</keyword>
  <keyword>stage IIC rectal cancer</keyword>
  <keyword>stage IIIA rectal cancer</keyword>
  <keyword>stage IA breast cancer</keyword>
  <keyword>stage IB breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage I esophageal cancer</keyword>
  <keyword>stage II esophageal cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage I hypopharyngeal cancer</keyword>
  <keyword>stage II hypopharyngeal cancer</keyword>
  <keyword>stage III hypopharyngeal cancer</keyword>
  <keyword>stage I laryngeal cancer</keyword>
  <keyword>stage II laryngeal cancer</keyword>
  <keyword>stage III laryngeal cancer</keyword>
  <keyword>stage I lip and oral cavity cancer</keyword>
  <keyword>stage II lip and oral cavity cancer</keyword>
  <keyword>stage III lip and oral cavity cancer</keyword>
  <keyword>stage I nasopharyngeal cancer</keyword>
  <keyword>stage II nasopharyngeal cancer</keyword>
  <keyword>stage III nasopharyngeal cancer</keyword>
  <keyword>stage I oropharyngeal cancer</keyword>
  <keyword>stage II oropharyngeal cancer</keyword>
  <keyword>stage III oropharyngeal cancer</keyword>
  <keyword>stage I paranasal sinus and nasal cavity cancer</keyword>
  <keyword>stage II paranasal sinus and nasal cavity cancer</keyword>
  <keyword>stage III paranasal sinus and nasal cavity cancer</keyword>
  <keyword>stage I salivary gland cancer</keyword>
  <keyword>stage II salivary gland cancer</keyword>
  <keyword>stage III salivary gland cancer</keyword>
  <keyword>tongue cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
    <mesh_term>Misonidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

